Abstract 2018P
Background
The standard treatment for localized high-risk upper tract urothelial carcinoma (LHR-UTUC) is radical nephroureterectomy (RNU). However, reduced tolerability and risk of renal insufficiency highlight the need for altered strategies that preserve functional nephron. This study aims to assess the efficacy and safety of a kidney-sparing surgery, with systemic therapy, in LHR-UTUC patients.
Methods
This study started in January 2019 and is ongoing. LHR-UTUC patients with solitary kidney, bilateral tumors, renal function insufficiency or ineligiblity for RNU, were included. Systemic therapy regimens were tailored based on pathology and biomarkers, including platinum-based chemotherapy (PC), Disitamab Vedotin (DV) and immune checkpoint inhibitors (ICIs). After endoscopic biopsy and laser ablation, patients received four cycles of systemic induction therapy, followed by endoscopic laser ablation or segmental ureterectomy. A 1-year course of immunotherapy was administered. The primary endpoints were metastasis and clinical complete response (cCR). Secondary endpoints were progression, renal function (estimated glomerular filtration rate, eGFR ml/min/1.73m2), and side effects.
Results
36 patients were enrolled. 30 underwent endoscopic thulium laser tumor ablation, 6 underwent segmental ureterectomy. The induction therapy comprised DV for 13 patients, PC for 3, and ICIs for 16. Recurrence was observed in 8 patients, repeat endoscopic laser ablation was performed. Salvage RNU was performed in 5 patients. Of those not achieving cCR, 2 underwent salvage RNU within 3 months, while the remaining 3 maintained their nephrons. Postoperative renal function impairment was noted in 5 patients, with a median pre-surgery eGFR of 61.54 (20.26, 113.77) and a median post-surgery eGFR of 56.28 (23.25, 117.04). No grade 3 or higher systemic toxicities were observed.
Conclusions
Preliminary findings indicate that our strategy demonstrated promising tumor control and satisfied renal function preservation. These results provide a foundation for further investigating nephron-sparing therapy in a select group of patients with localized high-risk UTUC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics Committee on Biomedical Research, West China Hospital of Sichuan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1987P - TROP-2 as a promising ADC target in penile squamous cell carcinoma that promotes cell proliferation by activating AKT through PKCα pathway
Presenter: Yi Tang
Session: Poster session 13
1988P - Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study
Presenter: Tanya Jindal
Session: Poster session 13
1989P - Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis
Presenter: Albert Jang
Session: Poster session 13
1990P - MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
Presenter: Chuanliang Cui
Session: Poster session 13
1992P - Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)
Presenter: Hedyeh Ebrahimi
Session: Poster session 13
1993P - A randomized, phase II trial to evaluate the safety and efficacy of eribulin mesylate in combination with atezolizumab compared to atezolizumab alone in subjects with locally advanced or metastatic transitional cell urothelial cancer where cisplatin-based treatment is not an option
Presenter: Anishka D'Souza
Session: Poster session 13
1994P - Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)
Presenter: Bradley McGregor
Session: Poster session 13
1995P - Insights into second-line (2L) systemic treatment (tx) receipt in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 13
1996P - Primary analysis of post-marketing surveillance (PMS) data for avelumab maintenance therapy in patients (pts) with curatively unresectable urothelial carcinoma (UC) in Japan
Presenter: Eiji Kikuchi
Session: Poster session 13